Latest Interviews
Showing 1–3 of 3 transcripts.
Clear all filters- a16z36 min
a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Amy Abernethy, Christina Lopes, Jorge Conde, Sonal
Amy Abernethy has been selected as the new Principal Deputy Commissioner of the FDA, where she aims to advance personalized medicine and accelerate evidence generation following her tenure at Flatiron Health. Her appointment aligns with the growing adoption of One Health strategies, a platform co-founded by Cristina Lopez that leverages spontaneous canine cancer data to validate human therapies. By treating dogs as natural clinical models with fully functional immune systems, this initiative promises to save costs in drug development and improve outcomes for both veterinary and human patients through shared real-world evidence.
- a16z27 min
a16z Podcast | Shifting Risk Mindsets, From Tech to Bio
Vijay Pande, Jorge Conde, Jeff Low, Jeffrey Lowe
This event guides tech founders through the critical challenges of translating their innovations into the biotechnology sector, emphasizing the necessity of treating biotech firms as data-driven enterprises. It details strategies to avoid operational pitfalls like "death by a thousand pilots" and outlines structural frameworks, such as LLC ring-fencing, to protect platform value while developing proprietary assets. Furthermore, the session provides actionable insights on diagnostics reimbursement, early validation "kill tests," and aligning hybrid investor syndicates to ensure sustainable growth in a high-barrier market.
- a16z29 min
a16z Podcast | Taking the Pulse on Bio
Jorge Conde, Vijay Pande, Malinka Walaliyadde, Jeffrey Low, Hannah
A16Z is shifting its bio-investment thesis from empirical science to engineered biology, prioritizing ventures where established biological mechanisms allow founders to apply AI and data-driven engineering to de-risk development. This approach targets sectors like diagnostic genomics and cell therapies, leveraging network effects and reusable platforms to transform unpredictable research into scalable, schedulable manufacturing processes. By favoring hybrid founders with expertise in both computer science and biology, the firm aims to accelerate innovation cycles and capture value in an era where technical execution supersedes novel biological discovery.